Friday, April 22, 2016, 34 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $688.65 to $595,517,648,860.00.

Highlighted Stocks Traded by Insiders:

Village Super Market (VLGEA) - FREE Research Report

Estate of Perry Sumas, who is Shareholder at Village Super Market, sold 5,544 shares at $24.95 on April 22, 2016. Following this transaction, the Shareholder owned 479,641 shares meaning that the stake was reduced by 1.14% with the 5,544-share transaction.

The shares most recently traded at $24.38, down $0.57, or 2.35% since the insider transaction. Historical insider transactions for Village Super Market go as follows:

  • 4-Week # shares sold: 30,611
  • 12-Week # shares sold: 70,595
  • 24-Week # shares sold: 155,846

The average volume for Village Super Market has been 33,600 shares per day over the past 30 days. Village Super Market has a market cap of $343.3 million and is part of the services sector and retail industry. Shares are down 8.16% year-to-date as of the close of trading on Friday.

Village Super Market, Inc. operates a chain of supermarkets in the United States. Its stores feature specialty departments, such as onsite bakery, an expanded delicatessen, natural and organic foods, ethnic and international foods, prepared foods, and pharmacies. The stock currently has a dividend yield of 4.12%. The company has a P/E ratio of 11.1. Currently, there are no analysts who rate Village Super Market a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VLGEA - FREE

TheStreet Quant Ratings rates Village Super Market as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Village Super Market Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Linear Technology (LLTC) - FREE Research Report

Quarles David A, who is Vp International Sales at Linear Technology, sold 2,000 shares at $46.17 on April 22, 2016. Following this transaction, the Vp International Sales owned 65,013 shares meaning that the stake was reduced by 2.98% with the 2,000-share transaction.

The shares most recently traded at $46.32, up $0.15, or 0.32% since the insider transaction. Historical insider transactions for Linear Technology go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 30,568
  • 24-Week # shares sold: 32,481

The average volume for Linear Technology has been 2.7 million shares per day over the past 30 days. Linear Technology has a market cap of $11.1 billion and is part of the technology sector and electronics industry. Shares are up 9.18% year-to-date as of the close of trading on Friday.

Linear Technology Corporation, together with its subsidiaries, designs, manufactures, and markets a line of analog integrated circuits worldwide. The stock currently has a dividend yield of 2.76%. The company has a P/E ratio of 22.9. Currently, there are 4 analysts who rate Linear Technology a buy, 4 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLTC - FREE

TheStreet Quant Ratings rates Linear Technology as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Linear Technology Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alimera (ALIM) - FREE Research Report

Bavp, L.P., who is 10% Owner at Alimera, sold 478,673 shares at $2.59 on April 22, 2016. Following this transaction, the 10% Owner owned 4.0 million shares meaning that the stake was reduced by 10.69% with the 478,673-share transaction.

The shares most recently traded at $2.37, down $0.22, or 9.27% since the insider transaction. Historical insider transactions for Alimera go as follows:

  • 4-Week # shares bought: 6,389
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 6,389
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 6,389
  • 24-Week # shares sold: 20,000

The average volume for Alimera has been 169,400 shares per day over the past 30 days. Alimera has a market cap of $103.1 million and is part of the health care sector and drugs industry. Shares are up 6.15% year-to-date as of the close of trading on Friday.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, Portugal, and the United Kingdom. The company focuses on diseases affecting the back of the eye or retina. Currently, there are 2 analysts who rate Alimera a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALIM - FREE

TheStreet Quant Ratings rates Alimera as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full Alimera Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.